LIVIVO - Search results -

Search results

Result 1 - 10 of total 629

Search options

Article ; Online: Reply to: Letter to the Editor from Malik et al.: Acute kidney injury following subcutaneous meloxicam administration.

Krekis, Alex / King, Jonathan N / D'Arcy-Howard, Duncan / Stapleton, Nadene / Elliott, Jonathan / Pelligand, Ludovic

Journal of veterinary pharmacology and therapeutics

2024 Volume 47, Issue 3, Page(s) 237–238

MeSH term(s)	Meloxicam/adverse effects ; Meloxicam/administration & dosage ; Meloxicam/therapeutic use ; Animals ; Acute Kidney Injury/chemically induced ; Acute Kidney Injury/veterinary ; Thiazoles/adverse effects ; Thiazoles/administration & dosage ; Thiazines/adverse effects ; Thiazines/administration & dosage ; Injections, Subcutaneous/veterinary ; Injections, Subcutaneous/adverse effects ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
Chemical Substances	Meloxicam (VG2QF83CGL) ; Thiazoles ; Thiazines ; Anti-Inflammatory Agents, Non-Steroidal
Language	English
Publishing date	2024-03-10
Publishing country	England
Document type	Letter
ZDB-ID	435216-6
ISSN	1365-2885 ; 0140-7783
ISSN (online)	1365-2885
ISSN	0140-7783
DOI	10.1111/jvp.13438
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2226: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effect of meloxicam or robenacoxib administration timing on renal function and postoperative analgesia in cats undergoing ovariohysterectomy: A randomized, blinded, controlled clinical trial.

Krekis, Alex / King, Jonathan N / D'Arcy-Howard, Duncan / Stapleton, Nadene / Elliott, Jonathan / Pelligand, Ludovic

Journal of veterinary pharmacology and therapeutics

2024 Volume 47, Issue 3, Page(s) 175–186

Abstract: We evaluated the effect of administration timing of meloxicam and robenacoxib on renal function, platelet cyclo-oxygenase and perioperative analgesia in 60 cats undergoing ovariohysterectomy, in a prospective randomized blinded controlled study. Twelve ... ...

Abstract	We evaluated the effect of administration timing of meloxicam and robenacoxib on renal function, platelet cyclo-oxygenase and perioperative analgesia in 60 cats undergoing ovariohysterectomy, in a prospective randomized blinded controlled study. Twelve cats were randomly allocated to one subcutaneous treatment group: meloxicam (0.2 mg/kg) or robenacoxib (2 mg/kg) at admission (MA, RA), at induction (MI, RI) and robenacoxib at the end of surgery (RE). All cats received the same anaesthesia protocol. Plasma renin activity (PRA), plasma creatinine, drug concentrations and serum thromboxane (TxB
MeSH term(s)	Animals ; Meloxicam/administration & dosage ; Meloxicam/pharmacology ; Meloxicam/therapeutic use ; Female ; Cats ; Hysterectomy/veterinary ; Pain, Postoperative/veterinary ; Pain, Postoperative/drug therapy ; Pain, Postoperative/prevention & control ; Diphenylamine/pharmacology ; Diphenylamine/administration & dosage ; Diphenylamine/analogs & derivatives ; Ovariectomy/veterinary ; Phenylacetates/administration & dosage ; Phenylacetates/pharmacology ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal/pharmacology ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Kidney/drug effects ; Analgesia/veterinary ; Analgesia/methods
Chemical Substances	Meloxicam (VG2QF83CGL) ; robenacoxib (Z588009C7C) ; Diphenylamine (9N3CBB0BIQ) ; Phenylacetates ; Anti-Inflammatory Agents, Non-Steroidal
Language	English
Publishing date	2024-01-18
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial, Veterinary ; Randomized Controlled Trial
ZDB-ID	435216-6
ISSN	1365-2885 ; 0140-7783
ISSN (online)	1365-2885
ISSN	0140-7783
DOI	10.1111/jvp.13427
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2226: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Determination of the route of excretion of robenacoxib (Onsior™) in cats and dogs: A pilot study.

King, Jonathan N / Jung, Martin

Journal of veterinary pharmacology and therapeutics

2021 Volume 44, Issue 3, Page(s) 411–416

Abstract: The objective of the studies was to determine the route of excretion, faecal or urinary, of the nonsteroidal anti-inflammatory drug (NSAID) robenacoxib (Onsior™) in cats and dogs. The studies employed a two-part crossover design in 4 beagle dogs (2 ... ...

Abstract	The objective of the studies was to determine the route of excretion, faecal or urinary, of the nonsteroidal anti-inflammatory drug (NSAID) robenacoxib (Onsior™) in cats and dogs. The studies employed a two-part crossover design in 4 beagle dogs (2 female and 2 male, age 36-41 months and body weight 9.0-10.3 kg) and a parallel group comparison of two groups each of 3 domestic short-hair cats (2 female and 4 castrated male, age 35-73 months and body weight 3.0-5.7 kg). Animals were administered single doses of 1 (dog) or 2 (cat) mg/kg of [
MeSH term(s)	Animals ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Cats/metabolism ; Diphenylamine/analogs & derivatives ; Dogs/metabolism ; Female ; Male ; Phenylacetates ; Pilot Projects
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Phenylacetates ; Diphenylamine (9N3CBB0BIQ) ; robenacoxib (Z588009C7C)
Language	English
Publishing date	2021-04-21
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial, Veterinary
ZDB-ID	435216-6
ISSN	1365-2885 ; 0140-7783
ISSN (online)	1365-2885
ISSN	0140-7783
DOI	10.1111/jvp.12973
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2226: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Determination of the route of excretion of robenacoxib (Onsior™) in cats and dogs: A pilot study

King, Jonathan N / Jung, Martin

Journal of veterinary pharmacology and therapeutics. 2021 May, v. 44, no. 3

2021

Abstract: The objective of the studies was to determine the route of excretion, faecal or urinary, of the nonsteroidal anti‐inflammatory drug (NSAID) robenacoxib (Onsior™) in cats and dogs. The studies employed a two‐part crossover design in 4 beagle dogs (2 ... ...

Abstract	The objective of the studies was to determine the route of excretion, faecal or urinary, of the nonsteroidal anti‐inflammatory drug (NSAID) robenacoxib (Onsior™) in cats and dogs. The studies employed a two‐part crossover design in 4 beagle dogs (2 female and 2 male, age 36–41 months and body weight 9.0–10.3 kg) and a parallel group comparison of two groups each of 3 domestic short‐hair cats (2 female and 4 castrated male, age 35–73 months and body weight 3.0–5.7 kg). Animals were administered single doses of 1 (dog) or 2 (cat) mg/kg of [¹⁴C]‐robenacoxib by intravenous (IV) and oral routes. Venous blood samples were taken and analysed for robenacoxib concentration. Faeces and urine were collected for 4 (cats) or 7 (dogs) days and analysed for radioactivity. Robenacoxib was eliminated rapidly from blood (≤ 8 hr). In dogs, expressed as the percentage of the administered dose and adjusted so that faecal plus urine recovery was 100%, the mean (SD) excretion in faeces and urine was, respectively, 64.6% (4.30) and 35.4% (4.3) after IV and 66.7% (6.9) and 33.3% (6.9) after oral administration. The respective values in cats, in faeces and urine, were 72.5% (4.6) and 27.5% (4.6) after IV and 78.5% (2.6) and 21.5% (2.6) after oral administration. In conclusion, excretion of systemically available robenacoxib in cats and dogs was mixed via both faeces and urine, but predominately faecal (~64.6% in dogs and ~72.5% in cats) and assumed to be via biliary excretion.
Keywords	Beagle ; administered dose ; blood ; body weight ; castration ; cross-over studies ; dogs ; excretion ; feces ; females ; intravenous injection ; males ; nonsteroidal anti-inflammatory agents ; oral administration ; pharmacology ; radioactivity ; urine
Language	English
Dates of publication	2021-05
Size	p. 411-416.
Publishing place	John Wiley & Sons, Ltd
Document type	Article
Note	NAL-AP-2-clean ; JOURNAL ARTICLE
ZDB-ID	435216-6
ISSN	1365-2885 ; 0140-7783
ISSN (online)	1365-2885
ISSN	0140-7783
DOI	10.1111/jvp.12973
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 2226: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib.

Lees, Peter / Toutain, Pierre-Louis / Elliott, Jonathan / Giraudel, Jerome M / Pelligand, Ludovic / King, Jonathan N

Journal of veterinary pharmacology and therapeutics

2022 Volume 45, Issue 4, Page(s) 325–351

Abstract: Robenacoxib is a veterinary-approved non-steroidal anti-inflammatory drug (NSAID) of the coxib group. It possesses anti-hyperalgesic, anti-inflammatory and anti-pyretic properties. Robenacoxib inhibits the cyclooxygenase (COX)-2 isoform of COX ... ...

Abstract	Robenacoxib is a veterinary-approved non-steroidal anti-inflammatory drug (NSAID) of the coxib group. It possesses anti-hyperalgesic, anti-inflammatory and anti-pyretic properties. Robenacoxib inhibits the cyclooxygenase (COX)-2 isoform of COX selectively (in vitro IC
MeSH term(s)	Animals ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Cat Diseases/chemically induced ; Cat Diseases/drug therapy ; Cats ; Cyclooxygenase 2/metabolism ; Cyclooxygenase 2 Inhibitors/adverse effects ; Diphenylamine/analogs & derivatives ; Diphenylamine/pharmacology ; Diphenylamine/therapeutic use ; Dog Diseases/drug therapy ; Dogs ; Phenylacetates/pharmacology ; Phenylacetates/therapeutic use
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Cyclooxygenase 2 Inhibitors ; Phenylacetates ; Diphenylamine (9N3CBB0BIQ) ; Cyclooxygenase 2 (EC 1.14.99.1) ; robenacoxib (Z588009C7C)
Language	English
Publishing date	2022-04-22
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	435216-6
ISSN	1365-2885 ; 0140-7783
ISSN (online)	1365-2885
ISSN	0140-7783
DOI	10.1111/jvp.13052
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2226: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: A Systematic Review of the Effect of Therapeutic Drug Monitoring on Patient Health Outcomes during Treatment with Carbapenems.

Luxton, Timothy N / King, Natalie / Wälti, Christoph / Jeuken, Lars J C / Sandoe, Jonathan A T

Antibiotics (Basel, Switzerland)

2022 Volume 11, Issue 10

Abstract: Adjusting dosing regimens based on measurements of carbapenem levels may improve carbapenem exposure in patients. This systematic review aims to describe the effect carbapenem therapeutic drug monitoring (TDM) has on health outcomes, including the ... ...

Abstract	Adjusting dosing regimens based on measurements of carbapenem levels may improve carbapenem exposure in patients. This systematic review aims to describe the effect carbapenem therapeutic drug monitoring (TDM) has on health outcomes, including the emergence of antimicrobial resistance (AMR). Four databases were searched for studies that reported health outcomes following adjustment to dosing regimens, according to measurements of carbapenem concentration. Bias in the studies was assessed with risk of bias analysis tools. Study characteristics and outcomes were tabulated and a narrative synthesis was performed. In total, 2 randomised controlled trials (RCTs), 17 non-randomised studies, and 19 clinical case studies were included. Significant variation in TDM practice was seen; consequently, a meta-analysis was unsuitable. Few studies assessed impacts on AMR. No significant improvement on health outcomes and no detrimental effects of carbapenem TDM were observed. Five cohort studies showed significant associations between achieving target concentrations and clinical success, including suppression of resistance. Studies in this review showed no obvious improvement in clinical outcomes when TDM is implemented. Optimisation and standardisation of carbapenem TDM practice are needed to improve intervention success and enable study synthesis. Further suitably powered studies of standardised TDM are required to assess the impact of TMD on clinical outcomes and AMR.
Language	English
Publishing date	2022-09-27
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics11101311
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: The Relationship between Internet Patient Satisfaction Ratings and COVID-19 Outcomes.

Stanley, Jonathan / Hensley, Mark / King, Ronald / Baum, Neil

Healthcare (Basel, Switzerland)

2023 Volume 11, Issue 10

Abstract: Our prior research showed that patient experience-as reported by Google, Yelp, and the Hospital Consumer Assessment of Healthcare Providers and Systems survey-is associated with health outcomes. Upon learning that COVID-19 mortality rates differed among ... ...

Abstract	Our prior research showed that patient experience-as reported by Google, Yelp, and the Hospital Consumer Assessment of Healthcare Providers and Systems survey-is associated with health outcomes. Upon learning that COVID-19 mortality rates differed among U.S. geographic areas, we sought to determine if COVID-19 outcomes were associated with patient experience. We reviewed daily, U.S.-county-level-accrued COVID-19 infections and deaths during the first year of the pandemic using each locality's mean online patient review rating, correcting for county-level demographic factors. We found doctor star ratings were significantly associated with COVID-19 outcomes. We estimated the absolute risk reduction (ARR) and relative risk reduction (RRR) for each outcome by comparing the real-world-observed outcomes, observed with the mean star rating, to the outcomes predicted by our model with a 0.3 unit higher average star rating. Geographic areas with higher patient satisfaction online review ratings in our models had substantially better COVID-19 outcomes. Our models predict that, had medical practices nationwide maintained a 4-star average online review rating-a 0.3-star increase above the current national average-the U.S may have experienced a nearly 11% lower COVID-19 infection rate and a nearly 17% lower death rate among those infected.
Language	English
Publishing date	2023-05-12
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2721009-1
ISSN	2227-9032
ISSN	2227-9032
DOI	10.3390/healthcare11101411
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Pharmacology, safety, efficacy and clinical uses of the COX‐2 inhibitor robenacoxib

Lees, Peter / Toutain, Pierre‐Louis / Elliott, Jonathan / Giraudel, Jerome M. / Pelligand, Ludovic / King, Jonathan N.

Journal of veterinary pharmacology and therapeutics. 2022 July, v. 45, no. 4

2022

Abstract: Robenacoxib is a veterinary‐approved non‐steroidal anti‐inflammatory drug (NSAID) of the coxib group. It possesses anti‐hyperalgesic, anti‐inflammatory and anti‐pyretic properties. Robenacoxib inhibits the cyclooxygenase (COX)‐2 isoform of COX ... ...

Abstract	Robenacoxib is a veterinary‐approved non‐steroidal anti‐inflammatory drug (NSAID) of the coxib group. It possesses anti‐hyperalgesic, anti‐inflammatory and anti‐pyretic properties. Robenacoxib inhibits the cyclooxygenase (COX)‐2 isoform of COX selectively (in vitro IC₅₀ ratios COX‐1:COX‐2, 129:1 in dogs, 32:1 in cats). At registered dosages (2 mg/kg subcutaneously in dogs and cats, 1–4 mg/kg orally in dogs and 1–2.4 mg/kg orally in cats), robenacoxib produces significant inhibition of COX‐2 whilst sparing COX‐1. The pharmacokinetic (PK) profile of robenacoxib is characterized by a high degree of binding to plasma proteins (>98%) and moderate volume of distribution (at steady state, 240 ml/kg in dogs and 190 ml/kg in cats). In consequence, the terminal half‐life in blood (<2 h) is short, despite moderate body clearance (0.81 L/kg/h) in dogs and low clearance (0.44 L/kg/h) in cats. Excretion is principally in the bile (65% in dogs and 72% in cats). Robenacoxib concentrates in inflamed tissues, and clinical efficacy is achieved with once‐daily dosing, despite the short blood terminal half‐life. In dogs, no relevant breed differences in robenacoxib PK have been detected. Robenacoxib has a wide safety margin; in healthy laboratory animals daily oral doses 20‐fold (dog, 1 month), eight‐fold (cat, 6 weeks) and five‐fold (dog, 6 months) higher than recommended clinical doses were well tolerated. Clinical efficacy and safety have been demonstrated in orthopaedic and soft tissue surgery, and in musculoskeletal disorders in dogs and cats.
Keywords	bile ; dogs ; excretion ; half life ; musculoskeletal system ; nonsteroidal anti-inflammatory agents ; orthopedics ; pharmacokinetics ; prostaglandin synthase ; surgery ; tissues
Language	English
Dates of publication	2022-07
Size	p. 325-351.
Publishing place	John Wiley & Sons, Ltd
Document type	Article
Note	REVIEW
ZDB-ID	435216-6
ISSN	1365-2885 ; 0140-7783
ISSN (online)	1365-2885
ISSN	0140-7783
DOI	10.1111/jvp.13052
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 2226: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Targeting the Endothelin A Receptor in IgA Nephropathy.

Kohan, Donald E / Barratt, Jonathan / Heerspink, Hiddo J L / Campbell, Kirk N / Camargo, Mariannne / Ogbaa, Ike / Haile-Meskale, Ruth / Rizk, Dana V / King, Andrew

Kidney international reports

2023 Volume 8, Issue 11, Page(s) 2198–2210

Abstract: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and carries a substantial risk of kidney failure. New agency-approved therapies, either specifically for IgAN or for chronic kidney disease (CKD) in general, hold ...

Abstract	Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and carries a substantial risk of kidney failure. New agency-approved therapies, either specifically for IgAN or for chronic kidney disease (CKD) in general, hold out hope for mitigating renal deterioration in patients with IgAN. The latest addition to this therapeutic armamentarium targets the endothelin-A receptor (ET
Language	English
Publishing date	2023-08-04
Publishing country	United States
Document type	Journal Article ; Review
ISSN	2468-0249
ISSN (online)	2468-0249
DOI	10.1016/j.ekir.2023.07.023
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: α4-Containing GABA

Macpherson, Tom / Dixon, Claire I / Robertson, Jonathan / Sindarto, Marsha M / Janak, Patricia H / Belelli, Delia / Lambert, Jeremy J / Stephens, David N / King, Sarah L

eNeuro

2023 Volume 10, Issue 8

Abstract: Extrasynaptic ... ...

Abstract	Extrasynaptic GABA
MeSH term(s)	Mice ; Animals ; Cocaine/pharmacology ; Nucleus Accumbens ; Receptors, GABA-A ; Neurons ; Mice, Knockout ; gamma-Aminobutyric Acid/pharmacology ; Receptors, Dopamine D2
Chemical Substances	Cocaine (I5Y540LHVR) ; Receptors, GABA-A ; gamma-Aminobutyric Acid (56-12-2) ; DRD2 protein, mouse ; Receptors, Dopamine D2
Language	English
Publishing date	2023-08-30
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	2800598-3
ISSN	2373-2822 ; 2373-2822
ISSN (online)	2373-2822
ISSN	2373-2822
DOI	10.1523/ENEURO.0236-23.2023
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito